凤凰网首页 手机凤凰网

凤凰卫视
  • [亚太] 上证指数 2319.12 (1.00%) 深证成指 9466.14 1.78% 恒生指数 19664.10 -1.06% 台北 7233.69 0.17% 韩国 1964.83 0.39%
  • [亚太] 日经 8841.22 -0.09% 澳大利亚 4348.48 0.45% 新西兰 3294.64 0.40% 印度孟买 17234.00 0.92% 新加坡 2916.26 0.75%
  • [美洲] 道琼斯 12660.50 -0.58% 纳斯达克 2816.55 0.40% 标普500 1316.33 -0.16% 加拿大 12466.50 0.02% 巴西 62904.20 -0.08%
  • [欧洲] 英国富时 5733.45 -1.07% 法国CAC 3318.76 -1.32% 德国DAX 6511.98 -0.43% 俄罗斯 1508.04 -0.44% Stoxx50 2436.62 -0.97%
  • [其他] 纽约原油 99.70 0.00% 纽约黄金 1738.40 0.00% 人民币/美元 6.33 0.00% 美元指数 78.83 0.00% 基金指数 3782.30 1.37%
  • [亚太] 上证指数 2319.12 (1.00%) 深证成指 9466.14 1.78% 恒生指数 19664.10 -1.06% 台北 7233.69 0.17% 韩国 1964.83 0.39%
  • [亚太] 日经 8841.22 -0.09% 澳大利亚 4348.48 0.45% 新西兰 3294.64 0.40% 印度孟买 17234.00 0.92% 新加坡 2916.26 0.75%
  • [美洲] 道琼斯 12660.50 -0.58% 纳斯达克 2816.55 0.40% 标普500 1316.33 -0.16% 加拿大 12466.50 0.02% 巴西 62904.20 -0.08%
  • [欧洲] 英国富时 5733.45 -1.07% 法国CAC 3318.76 -1.32% 德国DAX 6511.98 -0.43% 俄罗斯 1508.04 -0.44% Stoxx50 2436.62 -0.97%
  • [其他] 纽约原油 99.70 0.00% 纽约黄金 1738.40 0.00% 人民币/美元 6.33 0.00% 美元指数 78.83 0.00% 基金指数 3782.30 1.37%
免费注册
莱茵生物(002166)公告正文

莱茵生物:2017年第一季度报告全文

公告日期 2017-04-27
股票简称:莱茵生物 股票代码:002166
                桂林莱茵生物科技股份有限公司 2017 年第一季度报告全文




桂林莱茵生物科技股份有限公司

     2017 年第一季度报告




        2017 年 04 月




                                                                  1
                                    桂林莱茵生物科技股份有限公司 2017 年第一季度报告全文




                         第一节 重要提示


    公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真

实、准确、完整,不存在虚假记载、误导性陈述或者重大遗漏,并承担个别和

连带的法律责任。

    所有董事均已出席了审议本次季报的董事会会议。

    公司负责人秦本军、主管会计工作负责人周庆伟及会计机构负责人(会计主

管人员)张为鹏声明:保证季度报告中财务报表的真实、准确、完整。




                                                                                      2
                                                            桂林莱茵生物科技股份有限公司 2017 年第一季度报告全文




                                       第二节 公司基本情况

一、主要会计数据和财务指标

公司是否因会计政策变更及会计差错更正等追溯调整或重述以前年度会计数据
□ 是 √ 否

                                              本报告期                 上年同期              本报告期比上年同期增减

营业收入(元)                                  142,814,856.38            109,095,510.09                        30.91%

归属于上市公司股东的净利润(元)                 12,964,570.20             16,681,652.54                        -22.28%

归属于上市公司股东的扣除非经常性损
                                                 12,739,645.82             16,153,049.80                        -21.13%
益的净利润(元)

经营活动产生的现金流量净额(元)                -122,622,744.92           -22,417,818.53                       -446.99%

基本每股收益(元/股)                                      0.03                       0.04                      -25.00%

稀释每股收益(元/股)                                      0.03                       0.04                      -25.00%

加权平均净资产收益率                                      1.52%                    2.07%                         -0.55%

                                                                                             本报告期末比上年度末增
                                             本报告期末                上年度末
                                                                                                          减

总资产(元)                                   2,594,788,916.65         2,431,269,694.87                         6.73%

归属于上市公司股东的净资产(元)                858,423,938.32            845,734,726.59                         1.50%

非经常性损益项目和金额
√ 适用 □ 不适用
                                                                                                               单位:元

                         项目                               年初至报告期期末金额                   说明

非流动资产处置损益(包括已计提资产减值准备的冲销部分)                    -2,760.21

计入当期损益的政府补助(与企业业务密切相关,按照国家统
                                                                          28,000.00
一标准定额或定量享受的政府补助除外)

计入当期损益的对非金融企业收取的资金占用费                               183,168.46

除上述各项之外的其他营业外收入和支出                                      49,233.71

减:所得税影响额                                                          32,717.58

合计                                                                     224,924.38                  --

对公司根据《公开发行证券的公司信息披露解释性公告第 1 号——非经常性损益》定义界定的非经常性损益项目,以及把《公
开发行证券的公司信息披露解释性公告第 1 号——非经常性损益》中列举的非经常性损益项目界定为经常性损益的项目,应
说明原因
□ 适用 √ 不适用
公司报告期不存在将根据《公开发行证券的公司信息披露解释性公告第 1 号——非经常性损益》定义、列举的非经常性损益
项目界定为经常性损益的项目的情形。

                                                                                                                          3
                                                             桂林莱茵生物科技股份有限公司 2017 年第一季度报告全文


二、报告期末股东总数及前十名股东持股情况表

1、普通股股东总数和表决权恢复的优先股股东数量及前 10 名股东持股情况表

                                                                                                           单位:股

                                                             报告期末表决权恢复的优先
报告期末普通股股东总数                              69,548                                                      0
                                                             股股东总数(如有)

                                              前 10 名股东持股情况

                                                                   持有有限售条件         质押或冻结情况
     股东名称       股东性质      持股比例         持股数量
                                                                     的股份数量       股份状态          数量

秦本军           境内自然人            17.57%         76,840,512        57,630,384 质押                 41,130,000

姚新德           境内自然人             7.86%         34,361,643        25,771,232 质押                 34,361,543

梁定志           境内自然人             4.77%         20,874,447                  0

中央汇金资产管
                 国有法人               4.46%         19,491,600                  0
理有限责任公司

蒋安明           境内自然人             2.13%          9,304,728                  0

易红石           境内自然人             1.94%          8,500,000                  0

财通证券资管-
宁波银行-财通
证券资管莱茵 1 其他                     1.71%          7,498,703                  0
号集合资产管理
计划

蒋小三           境内自然人             1.24%          5,414,168                  0

杨晓涛           境内自然人             1.12%          4,889,400         4,889,400 质押                  4,889,400

陈兴华           境内自然人             0.80%          3,507,799                  0

                                      前 10 名无限售条件股东持股情况

                                                                                             股份种类
            股东名称                         持有无限售条件股份数量
                                                                                      股份种类          数量

梁定志                                                                  20,874,447 人民币普通股         20,874,447

中央汇金资产管理有限责任公司                                            19,491,600 人民币普通股         19,491,600

秦本军                                                                  19,210,128 人民币普通股         19,210,128

蒋安明                                                                   9,304,728 人民币普通股          9,304,728

姚新德                                                                   8,590,411 人民币普通股          8,590,411

易红石                                                                   8,500,000 人民币普通股          8,500,000

财通证券资管-宁波银行-财通
证券资管莱茵 1 号集合资产管理计                                          7,498,703 人民币普通股          7,498,703




                                                                                                                     4
                                                             桂林莱茵生物科技股份有限公司 2017 年第一季度报告全文


蒋小三                                                                  5,414,168 人民币普通股         5,414,168

陈兴华                                                                  3,507,799 人民币普通股         3,507,799

财通基金-兴业银行-富春 182 号
                                                                        1,950,000 人民币普通股         1,950,000
资产管理计划

                                  1.公司股东秦本军、蒋安明、蒋小三为兄弟关系,属于一致行动人。
                                  2.财通证券资管—宁波银行—财通证券资管莱茵 1 号集合资产管理计划系公司第一期员
上述股东关联关系或一致行动的      工持股计划账户。
说明                              3.姚新德系公司董事,杨晓涛系全资子公司莱茵投资执行董事,均与秦本军、蒋安明、
                                  蒋小三不存在一致行动关系。
                                  4.其他股东之间关系不详。

公司前 10 名普通股股东、前 10 名无限售条件普通股股东在报告期内是否进行约定购回交易
□ 是 √ 否
公司前 10 名普通股股东、前 10 名无限售条件普通股股东在报告期内未进行约定购回交易。


2、公司优先股股东总数及前 10 名优先股股东持股情况表

□ 适用 √ 不适用




                                                                                                                   5
                                                       桂林莱茵生物科技股份有限公司 2017 年第一季度报告全文




                                        第三节 重要事项

一、报告期主要财务数据、财务指标发生变动的情况及原因

√ 适用 □ 不适用


1.资产负债表项目变动情况
           项目            期末余额         期初余额         增减比例                    变动原因
货币资金                    83,678,727.82    29,544,484.58      183.23% 主要系报告期末新增银行贷款入账所致
                                                                          主要系报告期BT项目预付工程款增加尚
预付款项                    44,867,267.32    25,946,885.38       72.92%
                                                                          未结算所致
                                                                          系报告期支付新工厂的设备及工程款、上
其他非流动资产              55,134,314.92    39,686,332.63       38.93% 海植物健康产品研发中心项目建设增加
                                                                          并从“预付账款”重分类所致
                                                                          主要系报告期发放上年计提的绩效工资
应付职工薪酬                   959,599.03     9,995,369.60      -90.40%
                                                                          及奖金所致
                                                                          主要系报告期缴纳上年应交所得税等税
应交税费                     3,008,324.17     9,683,217.99      -68.93%
                                                                          款所致
                                                                          主要系报告期BT项目计提2亿元暂借款
应付利息                     2,095,788.89      783,184.38       167.60%
                                                                          利息所致
                                                                          主要系报告期BT项目增加暂借款2亿元
其他应付款                 204,929,755.47     7,240,142.66     2730.47%
                                                                          所致


2.利润表项目变动情况
           项目            本期金额         上期金额         增减比例                   变动原因
营业收入                   142,814,856.38   109,095,510.09      30.91% 主要系报告期BT项目收入增加所致

                                                                         主要系报告期BT项目收入增加成本相应
营业成本                   106,791,585.50    77,349,925.73      38.06%
                                                                         增加所致

                                                                         主要系报告期新设欧洲子公司等增加费用
销售费用                     4,444,084.16     3,287,095.20      35.20%
                                                                         所致

                                                                         主要系报告期研发费、新工厂试运行等费
管理费用                    11,368,529.09     8,405,145.52      35.26%
                                                                         用增加所致

                                                                         主要系报告期BT项目暂借款2亿元、以及
财务费用                     5,408,569.70     2,173,764.43     148.81%
                                                                         银行贷款增加所致

                                                                         系报告期广西兴安合作银行分红早于上年
投资收益                      356,579.17                       100.00%
                                                                         同期所致

                                                                         主要系上年同期母公司弥补以前年度亏损
所得税费用                   1,958,506.01     1,122,485.64      74.48%
                                                                         致所得税费用减少


                                                                                                              6
                                                             桂林莱茵生物科技股份有限公司 2017 年第一季度报告全文


其他综合收益                   -275,358.47          -155,855.62       -76.68% 系报告期外币报表折算差额所致


3.现金流量表项目变动情况
          项目              期末余额            期初余额           增减比例                  变动原因
                                                                                主要系报告期BT项目支付工程款增加所
经营活动现金流量净额        -122,622,744.92       -22,417,818.53     -446.99%
                                                                                致
                                                                                主要系报告期新工厂建设支出、上海植物
投资活动现金流量净额         -40,517,018.06       -18,910,645.02     -114.26% 健康产品研发中心项目建设等支出增加所
                                                                                致
筹资活动现金流量净额        218,091,546.31        34,152,705.55      538.58% 主要系报告期BT项目暂借款2亿元所致




二、重要事项进展情况及其影响和解决方案的分析说明

√ 适用 □ 不适用

       1.嘉吉公司订单
       2011年11月4日,公司披露了《关于签订日常经营重大合同的公告》。公司及全资子公司
LAYN USA与美国嘉吉股份有限公司营养健康事业部签订了一份关于甜菊糖最终产品的长期
独家《外包加工及供应协议》。2017年1季度,公司与美国嘉吉公司执行订单总计约109万美
元。
       2.BT项目合同
       2011年8月30日,公司披露了《关于全资子公司桂林莱茵投资有限公司签订BT项目合同
的公告》。莱茵投资与湖南省建筑工程集团总公司、湖南省建工园林工程有限公司组成的联
合体与桂林市临桂新区管理委员会、桂林市临桂新区城市建设投资有限公司、桂林市大禹水
利基础设施建设投资有限公司签订了《桂林市临桂新区防洪排涝及湖塘水系工程投资、建设
与移交合同书》,BT项目总投资估算约为人民币16.2亿元,建安总投资不低于人民币13.2亿
元,其余3亿元为工程建设其他费用(综合费用)。
       截至2017年3月31日,BT项目累计完成工程产值约12.5亿元。截至本报告期披露日,已累
计收到回购款7.32亿元。2017年1季度,莱茵投资实现营业收入65,085,868.78元,净利润
6,205,023.35元。(未经审计)
             重要事项概述                     披露日期                        临时报告披露网站查询索引

                                                              巨潮资讯网(www.cninfo.com.cn),《BT 项目合同实施进
BT 项目                              2017 年 04 月 11 日
                                                              展公告》(公告编号 2017-012)。

                                                              巨潮资讯网(www.cninfo.com.cn),《关于 BT 项目收到回
BT 项目                              2017 年 04 月 17 日
                                                              购款并偿还前期项目借款的公告》(公告编号 2017-013)。


                                                                                                                      7
                                                           桂林莱茵生物科技股份有限公司 2017 年第一季度报告全文


三、公司实际控制人、股东、关联方、收购人以及公司等承诺相关方在报告期内超期未履行
完毕的承诺事项

□ 适用 √ 不适用
公司报告期不存在公司实际控制人、股东、关联方、收购人以及公司等承诺相关方在报告期内超期未履行完毕的承诺事项。


四、对 2017 年 1-6 月经营业绩的预计

2017 年 1-6 月预计的经营业绩情况:
归属于上市公司股东的净利润为正值且不属于扭亏为盈的情形

2017 年 1-6 月归属于上市公司股东的净利润变动幅度                      150%         至                    200%

2017 年 1-6 月归属于上市公司股东的净利润变动区间(万元)            6,756.03       至                 8,107.23

2016 年 1-6 月归属于上市公司股东的净利润(万元)                                                      2,702.41

                                                           2 季度植物提取业务将继续保持较好的增长态势,同时 BT
业绩变动的原因说明
                                                           项目各单位工程也将陆续完成验收,预计将贡献较多收益。




五、以公允价值计量的金融资产

□ 适用 √ 不适用


六、违规对外担保情况

□ 适用 √ 不适用
公司报告期无违规对外担保情况。


七、控股股东及其关联方对上市公司的非经营性占用资金情况

□ 适用 √ 不适用
公司报告期不存在控股股东及其关联方对上市公司的非经营性占用资金。


八、报告期内接待调研、沟通、采访等活动登记表

□ 适用 √ 不适用
公司报告期内未发生接待调研、沟通、采访等活动。




                                                                                                                 8
                                                        桂林莱茵生物科技股份有限公司 2017 年第一季度报告全文




                                         第四节 财务报表

一、财务报表

1、合并资产负债表

编制单位:桂林莱茵生物科技股份有限公司
                                                                                                       单位:元

                 项目                        期末余额                               期初余额

流动资产:

    货币资金                                              83,678,727.82                          29,544,484.58

    结算备付金

    拆出资金

    以公允价值计量且其变动计入当
期损益的金融资产

    衍生金融资产

    应收票据

    应收账款                                              49,338,073.28                          55,679,497.52

    预付款项                                              44,867,267.32                          25,946,885.38

    应收保费

    应收分保账款

    应收分保合同准备金

    应收利息                                              10,960,669.53                          10,765,338.98

    应收股利

    其他应收款                                            18,190,029.96                          16,993,435.02

    买入返售金融资产

    存货                                                1,404,235,215.91                       1,334,766,280.84

    划分为持有待售的资产

    一年内到期的非流动资产

    其他流动资产                                          26,781,950.98                           26,111,666.70

流动资产合计                                            1,638,051,934.80                       1,499,807,589.02

非流动资产:

    发放贷款及垫款

    可供出售金融资产                                      72,040,932.08                          72,040,932.08



                                                                                                                  9
                                   桂林莱茵生物科技股份有限公司 2017 年第一季度报告全文


    持有至到期投资

    长期应收款                       16,960,000.00                        15,960,000.00

    长期股权投资

    投资性房地产                    253,468,325.05                       254,560,847.23

    固定资产                        153,153,527.42                       156,881,128.80

    在建工程                        345,394,521.09                       331,489,140.66

    工程物资

    固定资产清理

    生产性生物资产

    油气资产

    无形资产                         53,506,120.41                        53,659,879.60

    开发支出

    商誉

    长期待摊费用                        767,095.84                          871,699.81

    递延所得税资产                     6,312,145.04                        6,312,145.04

    其他非流动资产                   55,134,314.92                        39,686,332.63

非流动资产合计                      956,736,981.85                       931,462,105.85

资产总计                           2,594,788,916.65                    2,431,269,694.87

流动负债:

    短期借款                        470,000,000.00                       445,000,000.00

    向中央银行借款

    吸收存款及同业存放

    拆入资金

    以公允价值计量且其变动计入当
期损益的金融负债

    衍生金融负债

    应付票据

    应付账款                        202,342,891.78                       262,495,111.12

    预收款项                        502,506,837.11                       504,895,505.74

    卖出回购金融资产款

    应付手续费及佣金

    应付职工薪酬                        959,599.03                         9,995,369.60

    应交税费                           3,008,324.17                        9,683,217.99

    应付利息                           2,095,788.89                         783,184.38




                                                                                     10
                             桂林莱茵生物科技股份有限公司 2017 年第一季度报告全文


    应付股利

    其他应付款                204,929,755.47                         7,240,142.66

    应付分保账款

    保险合同准备金

    代理买卖证券款

    代理承销证券款

    划分为持有待售的负债

    一年内到期的非流动负债       3,873,920.00                        3,873,920.00

    其他流动负债               15,451,940.35                        14,406,976.49

流动负债合计                 1,405,169,056.80                    1,258,373,427.98

非流动负债:

    长期借款                  100,000,000.00                       100,000,000.00

    应付债券

      其中:优先股

               永续债

    长期应付款

    长期应付职工薪酬

    专项应付款                179,904,742.24                       179,909,426.92

    预计负债

    递延收益                   48,513,680.00                        44,513,680.00

    递延所得税负债               2,657,184.17                        2,657,184.17

    其他非流动负债

非流动负债合计                331,075,606.41                       327,080,291.09

负债合计                     1,736,244,663.21                    1,585,453,719.07

所有者权益:

    股本                      437,281,362.00                       437,281,362.00

    其他权益工具

      其中:优先股

               永续债

    资本公积                  261,669,420.58                       261,669,420.58

    减:库存股

    其他综合收益                 3,956,630.01                        4,231,988.48

    专项储备

    盈余公积                   16,517,129.99                        16,517,129.99



                                                                                11
                                                       桂林莱茵生物科技股份有限公司 2017 年第一季度报告全文


    一般风险准备

    未分配利润                                          138,999,395.74                         126,034,825.54

归属于母公司所有者权益合计                              858,423,938.32                         845,734,726.59

    少数股东权益                                            120,315.12                              81,249.21

所有者权益合计                                          858,544,253.44                         845,815,975.80

负债和所有者权益总计                                   2,594,788,916.65                       2,431,269,694.87


法定代表人:秦本军                 主管会计工作负责人:周庆伟                      会计机构负责人:张为鹏


2、母公司资产负债表

                                                                                                      单位:元

                 项目                       期末余额                               期初余额

流动资产:

    货币资金                                             64,017,327.13                          24,684,715.42

    以公允价值计量且其变动计入当
期损益的金融资产

    衍生金融资产

    应收票据

    应收账款                                             93,922,826.75                          95,907,436.43

    预付款项                                             28,293,447.01                          24,662,435.80

    应收利息

    应收股利

    其他应收款                                          163,539,005.22                         246,831,927.52

    存货                                                237,382,829.67                         235,574,724.35

    划分为持有待售的资产

    一年内到期的非流动资产

    其他流动资产                                         18,748,043.54                          18,418,826.45

流动资产合计                                            605,903,479.32                         646,080,065.97

非流动资产:

    可供出售金融资产                                     72,040,932.08                          72,040,932.08

    持有至到期投资

    长期应收款

    长期股权投资                                         72,725,582.27                          69,798,792.27

    投资性房地产                                        253,468,325.05                         254,560,847.23

    固定资产                                            148,142,277.05                         151,875,466.09


                                                                                                            12
                                   桂林莱茵生物科技股份有限公司 2017 年第一季度报告全文


    在建工程                        212,620,289.08                       199,508,416.85

    工程物资

    固定资产清理

    生产性生物资产

    油气资产

    无形资产                         52,946,120.41                        53,271,679.60

    开发支出

    商誉

    长期待摊费用

    递延所得税资产                     6,306,268.63                        6,306,268.63

    其他非流动资产                   28,492,326.80                        19,287,003.25

非流动资产合计                      846,742,121.37                       826,649,406.00

资产总计                           1,452,645,600.69                    1,472,729,471.97

流动负债:

    短期借款                        370,000,000.00                       375,000,000.00

    以公允价值计量且其变动计入当
期损益的金融负债

    衍生金融负债

    应付票据

    应付账款                         46,783,813.58                        66,022,097.78

    预收款项                           8,889,131.51                       11,317,998.14

    应付职工薪酬                        474,097.61                         8,722,833.65

    应交税费                           1,781,003.77                        3,182,349.37

    应付利息                                                                503,301.05

    应付股利

    其他应付款                       30,738,361.07                        23,185,978.44

    划分为持有待售的负债

    一年内到期的非流动负债             3,873,920.00                        3,873,920.00

    其他流动负债

流动负债合计                        462,540,327.54                       491,808,478.43

非流动负债:

    长期借款

    应付债券

      其中:优先股




                                                                                     13
                                       桂林莱茵生物科技股份有限公司 2017 年第一季度报告全文


               永续债

    长期应付款

    长期应付职工薪酬

    专项应付款                         179,904,742.24                          179,909,426.92

    预计负债

    递延收益                               48,513,680.00                        44,513,680.00

    递延所得税负债                          1,042,383.32                         1,042,383.32

    其他非流动负债

非流动负债合计                         229,460,805.56                          225,465,490.24

负债合计                               692,001,133.10                          717,273,968.67

所有者权益:

    股本                               437,281,362.00                          437,281,362.00

    其他权益工具

      其中:优先股

               永续债

    资本公积                           261,669,420.59                          261,669,420.59

    减:库存股

    其他综合收益

    专项储备

    盈余公积                               16,517,129.99                        16,517,129.99

    未分配利润                             45,176,555.01                        39,987,590.72

所有者权益合计                         760,644,467.59                          755,455,503.30

负债和所有者权益总计                  1,452,645,600.69                     1,472,729,471.97


3、合并利润表

                                                                                     单位:元

                 项目         本期发生额                          上期发生额

一、营业总收入                             142,814,856.38                      109,095,510.09

    其中:营业收入                         142,814,856.38                      109,095,510.09

           利息收入

           已赚保费

           手续费及佣金收入

二、营业总成本                             128,283,766.93                       91,657,088.44

    其中:营业成本                         106,791,585.50                       77,349,925.73



                                                                                           14
                                         桂林莱茵生物科技股份有限公司 2017 年第一季度报告全文


             利息支出

             手续费及佣金支出

             退保金

             赔付支出净额

             提取保险合同准备金净额

             保单红利支出

             分保费用

             税金及附加                      331,807.13                           441,222.56

             销售费用                       4,444,084.16                         3,287,095.20

             管理费用                      11,368,529.09                         8,405,145.52

             财务费用                       5,408,569.70                         2,173,764.43

             资产减值损失                     -60,808.65                               -65.00

    加:公允价值变动收益(损失以
“-”号填列)

         投资收益(损失以“-”号填
                                             356,579.17
列)

         其中:对联营企业和合营企业
的投资收益

         汇兑收益(损失以“-”号填列)

三、营业利润(亏损以“-”号填列)         14,887,668.62                        17,438,421.65

    加:营业外收入                            80,664.80                           393,716.53

         其中:非流动资产处置利得

    减:营业外支出                              6,191.30                           28,000.00

         其中:非流动资产处置损失               2,760.21

四、利润总额(亏损总额以“-”号填列)     14,962,142.12                        17,804,138.18

    减:所得税费用                          1,958,506.01                         1,122,485.64

五、净利润(净亏损以“-”号填列)         13,003,636.11                        16,681,652.54

    归属于母公司所有者的净利润             12,964,570.20                        16,681,652.54

    少数股东损益                              39,065.91

六、其他综合收益的税后净额                   -275,358.47                          -155,855.62

  归属母公司所有者的其他综合收益
                                             -275,358.47                          -155,855.62
的税后净额

    (一)以后不能重分类进损益的其
他综合收益

             1.重新计量设定受益计划净
负债或净资产的变动


                                                                                           15
                                                          桂林莱茵生物科技股份有限公司 2017 年第一季度报告全文


             2.权益法下在被投资单位不
能重分类进损益的其他综合收益中享
有的份额

    (二)以后将重分类进损益的其他
                                                               -275,358.47                          -155,855.62
综合收益

             1.权益法下在被投资单位以
后将重分类进损益的其他综合收益中
享有的份额

             2.可供出售金融资产公允价
值变动损益

             3.持有至到期投资重分类为
可供出售金融资产损益

             4.现金流量套期损益的有效
部分

             5.外币财务报表折算差额                            -275,358.47                          -155,855.62

             6.其他

  归属于少数股东的其他综合收益的
税后净额

七、综合收益总额                                             12,728,277.64                        16,525,796.92

    归属于母公司所有者的综合收益
                                                             12,689,211.73                        16,525,796.92
总额

    归属于少数股东的综合收益总额                                 39,065.91

八、每股收益:

    (一)基本每股收益                                                0.03                                 0.04

    (二)稀释每股收益                                                0.03                                 0.04

本期发生同一控制下企业合并的,被合并方在合并前实现的净利润为:0.00 元,上期被合并方实现的净利润为:0.00 元。


法定代表人:秦本军                      主管会计工作负责人:周庆伟                    会计机构负责人:张为鹏


4、母公司利润表

                                                                                                       单位:元

                 项目                           本期发生额                           上期发生额

一、营业收入                                                 68,521,355.68                        89,459,050.68

    减:营业成本                                             48,297,716.26                        67,124,287.30

           税金及附加                                           70,899.15

           销售费用                                           1,760,231.01                         1,732,211.65

           管理费用                                           8,536,649.20                         6,462,433.51


                                                                                                             16
                                      桂林莱茵生物科技股份有限公司 2017 年第一季度报告全文


         财务费用                       4,137,706.52                          2,640,175.65

         资产减值损失                      67,943.28

    加:公允价值变动收益(损失以
“-”号填列)

         投资收益(损失以“-”号填
                                          356,579.17
列)

         其中:对联营企业和合营企
业的投资收益

二、营业利润(亏损以“-”号填列)      6,006,789.43                         11,499,942.57

    加:营业外收入                         41,140.00                           393,716.53

         其中:非流动资产处置利得

    减:营业外支出                          6,191.30                            28,000.00

         其中:非流动资产处置损失           2,760.21

三、利润总额(亏损总额以“-”号填
                                        6,041,738.13                         11,865,659.10
列)

    减:所得税费用                        852,773.84

四、净利润(净亏损以“-”号填列)      5,188,964.29                         11,865,659.10

五、其他综合收益的税后净额

    (一)以后不能重分类进损益的
其他综合收益

             1.重新计量设定受益计划
净负债或净资产的变动

             2.权益法下在被投资单位
不能重分类进损益的其他综合收益中
享有的份额

    (二)以后将重分类进损益的其
他综合收益

             1.权益法下在被投资单位
以后将重分类进损益的其他综合收益
中享有的份额

             2.可供出售金融资产公允
价值变动损益

             3.持有至到期投资重分类
为可供出售金融资产损益

             4.现金流量套期损益的有
效部分

             5.外币财务报表折算差额



                                                                                        17
                                                 桂林莱茵生物科技股份有限公司 2017 年第一季度报告全文


           6.其他

六、综合收益总额                                    5,188,964.29                        11,865,659.10

七、每股收益:

     (一)基本每股收益                                     0.01                                 0.03

     (二)稀释每股收益                                     0.01                                 0.03


5、合并现金流量表

                                                                                             单位:元

               项目                 本期发生额                             上期发生额

一、经营活动产生的现金流量:

     销售商品、提供劳务收到的现金                 84,763,814.43                         91,614,734.76

     客户存款和同业存放款项净增
加额

     向中央银行借款净增加额

     向其他金融机构拆入资金净增
加额

     收到原保险合同保费取得的现


     收到再保险业务现金净额

     保户储金及投资款净增加额

     处置以公允价值计量且其变动
计入当期损益的金融资产净增加额

     收取利息、手续费及佣金的现金

     拆入资金净增加额

     回购业务资金净增加额

     收到的税费返还                                4,955,793.92                          5,865,452.58

     收到其他与经营活动有关的现
                                                   1,056,428.35                          1,210,175.17


经营活动现金流入小计                              90,776,036.70                         98,690,362.51

     购买商品、接受劳务支付的现金                171,651,915.10                         91,181,389.78

     客户贷款及垫款净增加额

     存放中央银行和同业款项净增
加额

     支付原保险合同赔付款项的现


     支付利息、手续费及佣金的现金


                                                                                                   18
                                     桂林莱茵生物科技股份有限公司 2017 年第一季度报告全文


     支付保单红利的现金

     支付给职工以及为职工支付的
                                     20,552,769.23                          12,784,657.05
现金

     支付的各项税费                    8,529,830.58                         10,173,557.09

     支付其他与经营活动有关的现
                                     12,664,266.71                           6,968,577.12


经营活动现金流出小计                213,398,781.62                         121,108,181.04

经营活动产生的现金流量净额          -122,622,744.92                        -22,417,818.53

二、投资活动产生的现金流量:

     收回投资收到的现金

     取得投资收益收到的现金             356,579.17

     处置固定资产、无形资产和其他
                                                                             5,000,000.00
长期资产收回的现金净额

     处置子公司及其他营业单位收
到的现金净额

     收到其他与投资活动有关的现
                                       4,000,000.00


投资活动现金流入小计                   4,356,579.17                          5,000,000.00

     购建固定资产、无形资产和其他
                                     44,873,597.23                          21,694,645.02
长期资产支付的现金

     投资支付的现金

     质押贷款净增加额

     取得子公司及其他营业单位支
付的现金净额

     支付其他与投资活动有关的现
                                                                             2,216,000.00


投资活动现金流出小计                 44,873,597.23                          23,910,645.02

投资活动产生的现金流量净额           -40,517,018.06                        -18,910,645.02

三、筹资活动产生的现金流量:

     吸收投资收到的现金

     其中:子公司吸收少数股东投资
收到的现金

     取得借款收到的现金             260,000,000.00                          70,000,000.00

     发行债券收到的现金

     收到其他与筹资活动有关的现
                                    210,794,900.00                           1,000,000.00





                                                                                       19
                                                 桂林莱茵生物科技股份有限公司 2017 年第一季度报告全文


筹资活动现金流入小计                             470,794,900.00                          71,000,000.00

     偿还债务支付的现金                          235,000,000.00                          30,000,000.00

     分配股利、利润或偿付利息支付
                                                   6,703,353.69                           4,847,294.45
的现金

     其中:子公司支付给少数股东的
股利、利润

     支付其他与筹资活动有关的现
                                                  11,000,000.00                           2,000,000.00


筹资活动现金流出小计                             252,703,353.69                          36,847,294.45

筹资活动产生的现金流量净额                       218,091,546.31                          34,152,705.55

四、汇率变动对现金及现金等价物的
                                                      25,512.27                            -208,076.32
影响

五、现金及现金等价物净增加额                      54,977,295.60                          -7,383,834.32

     加:期初现金及现金等价物余额                 28,701,432.22                         195,797,923.76

六、期末现金及现金等价物余额                      83,678,727.82                         188,414,089.44


6、母公司现金流量表

                                                                                              单位:元

              项目                  本期发生额                             上期发生额

一、经营活动产生的现金流量:

     销售商品、提供劳务收到的现金                 70,440,378.18                          64,388,416.90

     收到的税费返还                                4,955,793.92                           5,865,452.58

     收到其他与经营活动有关的现
                                                    262,977.59                            1,206,375.68


经营活动现金流入小计                              75,659,149.69                          71,460,245.16

     购买商品、接受劳务支付的现金                 58,632,378.67                          41,338,591.38

     支付给职工以及为职工支付的
                                                  17,093,528.58                           9,815,663.33
现金

     支付的各项税费                                1,986,568.61                            343,702.61

     支付其他与经营活动有关的现
                                                   7,764,418.77                           4,843,138.29


经营活动现金流出小计                              85,476,894.63                          56,341,095.61

经营活动产生的现金流量净额                        -9,817,744.94                          15,119,149.55

二、投资活动产生的现金流量:

     收回投资收到的现金

     取得投资收益收到的现金                         356,579.17


                                                                                                    20
                                    桂林莱茵生物科技股份有限公司 2017 年第一季度报告全文


     处置固定资产、无形资产和其他
                                                                            5,000,000.00
长期资产收回的现金净额

     处置子公司及其他营业单位收
到的现金净额

     收到其他与投资活动有关的现
                                      4,000,000.00


投资活动现金流入小计                  4,356,579.17                          5,000,000.00

     购建固定资产、无形资产和其他
                                     37,801,550.24                          6,039,168.67
长期资产支付的现金

     投资支付的现金                   2,185,410.00                         15,550,000.00

     取得子公司及其他营业单位支
付的现金净额

     支付其他与投资活动有关的现
                                                                            2,216,000.00


投资活动现金流出小计                 39,986,960.24                         23,805,168.67

投资活动产生的现金流量净额          -35,630,381.07                        -18,805,168.67

三、筹资活动产生的现金流量:

     吸收投资收到的现金

     取得借款收到的现金             230,000,000.00                         50,000,000.00

     发行债券收到的现金

     收到其他与筹资活动有关的现
                                    160,000,000.00


筹资活动现金流入小计                390,000,000.00                         50,000,000.00

     偿还债务支付的现金             235,000,000.00                         30,000,000.00

     分配股利、利润或偿付利息支付
                                      4,042,953.70                          3,778,544.45
的现金

     支付其他与筹资活动有关的现
                                     66,115,100.00                         37,140,000.00


筹资活动现金流出小计                305,158,053.70                         70,918,544.45

筹资活动产生的现金流量净额           84,841,946.30                        -20,918,544.45

四、汇率变动对现金及现金等价物的
                                           764.68                             -10,817.75
影响

五、现金及现金等价物净增加额         39,394,584.97                        -24,615,381.32

     加:期初现金及现金等价物余额    24,622,742.16                        193,484,716.82

六、期末现金及现金等价物余额         64,017,327.13                        168,869,335.50




                                                                                      21
                             桂林莱茵生物科技股份有限公司 2017 年第一季度报告全文


二、审计报告

第一季度报告是否经过审计
□ 是 √ 否
公司第一季度报告未经审计。




                                          桂林莱茵生物科技股份有限公司


                                          法定代表人:

                                                                  秦本军

                                                   二〇一七年四月二十五日




                                                                              22
数据加载中...
prevnext
手机查看股票